Skip to main content

Top Bar Menu

Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • News Library

Sign Up For Emails

Patient Gateways

Top Bar Menu

Sign Up For Emails

  • Non-Small Cell Lung Cancer
    • NSCLC
    • ALK
    • EGFR
    • KRAS
    • Rare Mutations
  • Small Cell Lung Cancer
  • Resources
    • Clinical Trials
    • Find a Cancer Center
    • News Library

Main navigation

Close Menu
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials
  • Clinical Trials

Patient Gateway

News Library

You are about to leave the Patient Gateway

You’re one click away from learning about one of our most valued sponsors. Read about how they’re making a difference in patients’ lives.

ProceedCancel

  • Drs Basu Roy and Forde

    Video

    April 12, 2022

    Immunotherapy in Early-Stage Lung Cancer

    Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCH), at the 2022 AACR meeting about his findings on immunotherapy in early...
    READ MORE about Immunotherapy in Early-Stage Lung Cancer ›

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Current page 11
SHARE

The Patient Gateways are a project of LUNGevity Foundation, an organization transforming how people are diagnosed and live with lung cancer. Learn more here.

Privacy policy | Contact us

 

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

 

Copyright © 2026 LUNGevity Foundation. All rights reserved.